Year, and Adjusted EBITDA of $11.7 Million, up 34% Year-Over YearNine Month Revenue of $135.8 Million, up 11% Year-over-Year; ...

Researchers improved extracting a natural thickener from fenugreek seeds using cold plasma tech. This process boosts yield & ...

In patients with Long COVID, a new study has revealed structural association between circulating microclots and neutrophil ...

In a groundbreaking study that shines a light on the complex pathology of long COVID, researchers have uncovered a ...

Background Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterised by thrombosis, pregnancy ...

Background Globally, an estimated 296 million individuals live with chronic hepatitis B virus (HBV) infection, carrying ...

Year, and Adjusted EBITDA of $11.7 Million, up 34% Year-Over YearNine Month Revenue of $135.8 Million, up 11% Year-over-Year; Adjusted EBITDA ...

Biohaven Ltd. narrows focus to three late-stage clinical programs and implements cost-cutting to address heavy R&D spending.

Cerus Corporation (Nasdaq: CERS) announced today financial results for the third quarter ended September 30, 2025, and provided a business update.

The AI Portfolio also ended in negative territory, falling 0.8%. Total portfolio returns now stand at 6% since inception. The top gaining stocks were Twilio (+17.7%), Amazon (+8.6%) and Marvell ...